Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases

D. Suster, M. Michal, H. Huang, S. Ronen, S. Springborn, M. Debiec-Rychter, SD. Billings, JR. Goldblum, BP. Rubin, M. Michal, S. Suster, AC. Mackinnon

. 2020 ; 33 (12) : 2520-2533. [pub] 20200608

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004790

Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade soft tissue neoplasm preferentially arising in the extremities of young to middle-aged adults characterized histologically by a variegated appearance and absence of a distinctive immunophenotype. Herein we have evaluated a series of 73 cases of MIFS to define potential features and markers that may facilitate diagnosis. An immunohistochemical study with a large panel of antibodies showed strong positivity of the tumor cells for bcl-1 (94.5%), FXIIIa (89%), CD10 (80%), and D2-40 (56%). FISH and array comparative genomic hybridization (aCGH) were performed in a large subset of cases to investigate the utility for detecting the TGFBR3 and OGA t(1;10) rearrangement and BRAF abnormalities. Using a combination of FISH and/or aCGH, t(1;10) was detected in only 3 of 54 cases (5.5%). The aCGH study also demonstrated amplification of VGLL3 on chromosome 3 that was detected in 8 of 20 cases (40%). BRAF alterations were observed by FISH in 4 of 70 cases (5.7%) and correlated with gain of chromosome 3p12 (VGLL3). A novel fusion transcript involving exon 6 of ZNF335 and exon 10 of BRAF was identified in one case. Demonstration of amplification of VGLL3 on chromosome 3 in combination with expression of bcl-1 and FXIIIa may help support the diagnosis, however, due to their low specificity these markers are not sufficient for a definitive diagnosis in the absence of the appropriate clinical-pathological context. Until a more robust genetic or immunohistochemical signature is identified, the diagnosis of MIFS rests on its characteristic clinicopathological features.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004790
003      
CZ-PrNML
005      
20220127144955.0
007      
ta
008      
220113s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41379-020-0580-6 $2 doi
035    __
$a (PubMed)32514165
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Suster, David $u Departments of Pathology, Mount Sinai Hospital and the Icahn School of Medicine, New York, NY, USA
245    10
$a Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases / $c D. Suster, M. Michal, H. Huang, S. Ronen, S. Springborn, M. Debiec-Rychter, SD. Billings, JR. Goldblum, BP. Rubin, M. Michal, S. Suster, AC. Mackinnon
520    9_
$a Myxoinflammatory fibroblastic sarcoma (MIFS) is a rare, low-grade soft tissue neoplasm preferentially arising in the extremities of young to middle-aged adults characterized histologically by a variegated appearance and absence of a distinctive immunophenotype. Herein we have evaluated a series of 73 cases of MIFS to define potential features and markers that may facilitate diagnosis. An immunohistochemical study with a large panel of antibodies showed strong positivity of the tumor cells for bcl-1 (94.5%), FXIIIa (89%), CD10 (80%), and D2-40 (56%). FISH and array comparative genomic hybridization (aCGH) were performed in a large subset of cases to investigate the utility for detecting the TGFBR3 and OGA t(1;10) rearrangement and BRAF abnormalities. Using a combination of FISH and/or aCGH, t(1;10) was detected in only 3 of 54 cases (5.5%). The aCGH study also demonstrated amplification of VGLL3 on chromosome 3 that was detected in 8 of 20 cases (40%). BRAF alterations were observed by FISH in 4 of 70 cases (5.7%) and correlated with gain of chromosome 3p12 (VGLL3). A novel fusion transcript involving exon 6 of ZNF335 and exon 10 of BRAF was identified in one case. Demonstration of amplification of VGLL3 on chromosome 3 in combination with expression of bcl-1 and FXIIIa may help support the diagnosis, however, due to their low specificity these markers are not sufficient for a definitive diagnosis in the absence of the appropriate clinical-pathological context. Until a more robust genetic or immunohistochemical signature is identified, the diagnosis of MIFS rests on its characteristic clinicopathological features.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    12
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a srovnávací genomová hybridizace $7 D055028
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibroblasty $x chemie $x patologie $7 D005347
650    _2
$a fibrosarkom $x chemie $x genetika $x patologie $7 D005354
650    _2
$a amplifikace genu $7 D005784
650    _2
$a fúze genů $7 D050939
650    _2
$a genová přestavba $7 D015321
650    _2
$a genetická predispozice k nemoci $7 D020022
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    12
$a imunohistochemie $7 D007150
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a diagnostické techniky molekulární $7 D025202
650    _2
$a fenotyp $7 D010641
650    _2
$a nádory měkkých tkání $x chemie $x genetika $x patologie $7 D012983
650    _2
$a translokace genetická $7 D014178
650    _2
$a mladý dospělý $7 D055815
651    _2
$a Evropa $7 D005060
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Michal, Michael $u Sikl's Department of Pathology, Charles University, Plsen, Czech Republic
700    1_
$a Huang, Huiya $u Medical College of Wisconsin, Milwaukee, WI, USA
700    1_
$a Ronen, Shira $u Medical College of Wisconsin, Milwaukee, WI, USA
700    1_
$a Springborn, Stephanie $u Medical College of Wisconsin, Milwaukee, WI, USA
700    1_
$a Debiec-Rychter, Maria $u Department of Human Genetics, KU Leuven and University Hospitals, Leuven, Belgium
700    1_
$a Billings, Steven D $u The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Goldblum, John R $u The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Rubin, Brian P $u The Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Michal, Michal $u Sikl's Department of Pathology, Charles University, Plsen, Czech Republic
700    1_
$a Suster, Saul $u Medical College of Wisconsin, Milwaukee, WI, USA
700    1_
$a Mackinnon, A Craig $u University of Alabama at Birmingham, Birmingham, AL, USA. amackinnon@uabmc.edu
773    0_
$w MED00003380 $t Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc $x 1530-0285 $g Roč. 33, č. 12 (2020), s. 2520-2533
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32514165 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127144952 $b ABA008
999    __
$a ok $b bmc $g 1752088 $s 1155939
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 33 $c 12 $d 2520-2533 $e 20200608 $i 1530-0285 $m Modern pathology $n Mod Pathol $x MED00003380
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace